• Phio Pharmaceuticals will present final Phase 1b results for PH-762 at SITC’s annual meeting in Phoenix on November 7, 2026.
• Findings suggest PH-762 is well tolerated and could reduce the extent of surgery for cutaneous squamous cell carcinoma.
• A Phase 2b study is planned for the first half of 2027 to further evaluate safety and efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611060905NEWSFILECNPR____20261106_322719_1) on November 06, 2026, and is solely responsible for the information contained therein.